Cargando…

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate

Vaccination with DNA-SIV + ALVAC-SIV + gp120 alum results in inflammasome activation, high levels of IL-1β production, emergency myelopoiesis, and the egress of CXCR4(+) CD14(+) pre-monocytes from bone marrow. Previously we have shown that this vaccine-induced innate monocyte memory is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaccari, Monica, Fourati, Slim, Brown, Dallas R., Silva de Castro, Isabela, Bissa, Massimiliano, Schifanella, Luca, Doster, Melvin N., Foulds, Kathryn E., Roederer, Mario, Koup, Richard A., Sui, Yongjun, Berzofsky, Jay A., Sekaly, Rafick-Pierre, Franchini, Genoveffa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527580/ https://www.ncbi.nlm.nih.gov/pubmed/31139193 http://dx.doi.org/10.3389/fimmu.2019.01072

Ejemplares similares

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
por: Liyanage, NP, et al.
Publicado: (2012)

Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
por: Gorini, Giacomo, et al.
Publicado: (2020)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC
por: Bissa, Massimiliano, et al.
Publicado: (2023)

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α(4)β(7)
por: Lertjuthaporn, Sakaorat, et al.
Publicado: (2018)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4(+) T-Cells
por: Bissa, Massimiliano, et al.
Publicado: (2023)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

T Cell Subsets in the Germinal Center: Lessons from the Macaque Model
por: Vaccari, Monica, et al.
Publicado: (2018)

The first structure of HIV-1 gp120 with CD4 and CCR5 receptors
por: Guan, Yongjun
Publicado: (2019)

Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide
por: Gutowska, Anna, et al.
Publicado: (2022)

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant
por: Liang, F, et al.
Publicado: (2012)

Physiological Corticosterone Attenuates gp120-Mediated Microglial Activation and Is Associated with Reduced Anxiety-Like Behavior in gp120-Expressing Mice
por: Moss, Emaya M., et al.
Publicado: (2023)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

Internalization and Axonal Transport of the HIV Glycoprotein gp120
por: Berth, Sarah, et al.
Publicado: (2015)

Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
por: Drummer, Heidi E., et al.
Publicado: (2013)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells
por: Harenberg, Anke, et al.
Publicado: (2008)

Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp120
por: Langford, Dianne, et al.
Publicado: (2005)

Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 ± IL-15
por: McKee, Hayley J, et al.
Publicado: (2004)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
por: Sekaly, Rafick-Pierre
Publicado: (2008)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

Behavioral Evidence for a Tau and HIV-gp120 Interaction
por: Vijayan, Murali, et al.
Publicado: (2022)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides
por: Kassler, Kristin, et al.
Publicado: (2011)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response
por: Visciano, Maria Luisa, et al.
Publicado: (2008)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

Deletion of the Highly Conserved N-Glycan at Asn260 of HIV-1 gp120 Affects Folding and Lysosomal Degradation of gp120, and Results in Loss of Viral Infectivity
por: Mathys, Leen, et al.
Publicado: (2014)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

HLA-C increases HIV-1 infectivity and is associated with gp120
por: Matucci, Andrea, et al.
Publicado: (2008)

The C5 region of HIV-1 gp120 binds specific
por: Dalgleish, A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_9o9ktka05hnvelqo4vrr7ccvni